PT - JOURNAL ARTICLE AU - Florencia A. Monge AU - Pradeepkumar Jagadesan AU - Virginie Bondu AU - Patrick L. Donabedian AU - Linnea Ista AU - Eva Y. Chi AU - Kirk S. Schanze AU - David G Whitten AU - Alison M. Kell TI - Highly Effective Inactivation of SARS-CoV-2 by Conjugated Polymers and Oligomers AID - 10.1101/2020.09.29.20204164 DP - 2020 Jan 01 TA - medRxiv PG - 2020.09.29.20204164 4099 - http://medrxiv.org/content/early/2020/10/06/2020.09.29.20204164.short 4100 - http://medrxiv.org/content/early/2020/10/06/2020.09.29.20204164.full AB - The current Covid-19 Pandemic caused by the highly contagious SARS-CoV-2 virus has proven extremely difficult to prevent or control. Currently there are few treatment options and very few long-lasting disinfectants available to prevent the spread. While masks and protective clothing and “social distancing” may offer some protection, their use has not always halted or slowed the spread. Several vaccines are currently undergoing testing; however there is still a critical need to provide new methods for inactivating the virus before it can spread and infect humans. In the present study we examined the inactivation of SARS-CoV-2 by synthetic conjugated polymers and oligomers developed in our laboratories as antimicrobials for bacteria, fungi and non-enveloped viruses. Our results show that we can obtain highly effective light induced inactivation with several of these oligomers and polymers including irradiation with near-UV and visible light. With both the oligomers and polymers, we can reach several logs of inactivation with relatively short irradiation times. Our results suggest several applications involving the incorporation of these materials in wipes, sprays, masks and clothing and other Personal Protection Equipment (PPE) that can be useful in preventing infections and the spreading of this deadly virus and future outbreaks from similar viruses.Competing Interest StatementK. Schanze and D. Whitten have an interest in BioSafe, LLC which has licensed conjugated polymers and oligomers for use as antimicrobials.Funding StatementWork was supported in part by the following sources of funding: NIH grant 1K22AI141680-01A1 Welch Foundation Grant Grant AX-0045-20110629 None of the authors received payment for any aspect of the work.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:No IRB approval was needed for the study.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData can be provided upon request.